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Abstract
Volatile organic compound (VOC)-based diagnostics have great potential to be the next 
generation of screening tools for pathogen identification and infectious disease manage-
ment. VOCs are low molecular weight metabolic compounds that have high vapor pres-
sures and low boiling points, both of which facilitate evaporation at ambient temperatures. 
There is increasing evidence that particular VOCs, or profiles of VOCs, are unique to vari-
ous disease states. Different pathogenic species have been found to produce characteristic 
profiles of VOCs by virtue of their distinct metabolisms. The detection of these metabo-
lite profiles from patient samples could provide an effective means of rapid, non-invasive 
pathogen identification, thus enabling early diagnosis and treatment. In this review, we will 
discuss the potential of VOC profiles to be utilized as biomarkers of pathogenic infection, 
with a focus on bacterial pathogens. Herein we describe the common methods for clinical 
VOC sample collection, provide an overview of the various instruments and techniques 
used for VOC detection and analysis, and summarize the key findings of recent studies that 
have investigated VOC biomarkers in various infectious diseases. We will also discuss the 
challenges associated with translating VOC analysis into a clinical diagnostic tool.
Keywords: volatile organic compounds, VOCs, metabolites, signatures, biomarkers, 
profiles, pathogen identification, infectious diseases, clinical diagnostics, non-invasive 
tools, antibiotic resistance
1. Introduction
Although VOC identification has only been enabled by the development of sophisticated ana-
lytical techniques in the last two decades, the premise that VOC profiles can be used as bio-
markers for disease can be traced back to ancient times, when physicians diagnosed diseases 
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based on their senses. The ancient Greek physician Hippocrates (460–370 BC) is said to have 
poured human sputum over hot coals to liberate the distinct odors indicative of tuberculosis 
infection. In the early 20th century, it was postulated that bad breath in many mammalian 
species may be sexually unattractive precisely because it is indicative of disease [1]. Currently, 
there is a great public health need to develop rapid, non-invasive methods of identifying 
pathogens and determining their antibiotic resistance or susceptibility status in order to effec-
tively treat infectious diseases. Conventional diagnostic methods offer limited sensitivity and 
specificity, and can be expensive, invasive for patients, and time-consuming, often requiring 
several days for cell culture and low-throughput microscopy assays. Delays and limitations in 
diagnostic results often lead to the initiation of untargeted therapies, such as treatment with 
broad-spectrum antibiotics, which contribute to the evolution of antibiotic-resistant pathogens.
VOCs represent a diverse group of carbon-based molecules, including alcohols, ketones, 
aldehydes, hydrocarbons, isocyanates, amines, terpenes and sulfides [2]. VOCs are generally 
short-lived and become rapidly diluted in microenvironments. Altering growth conditions 
can modulate VOC profiles, reflecting the unique metabolic state of an organism in specific 
environments. Many animals, plants, and microbes have evolved chemical sensing mecha-
nisms that can detect minute quantities of VOCs released during growth to protect against 
antagonists and to act as signaling molecules for intercellular communication. For example, 
plants use volatiles to communicate with pollinators and to coordinate growth with their own 
kind to out-compete foreign species.
As a result of normal metabolic functions, the healthy human body produces a vast number 
of VOCs that are liberated in exhaled breath, skin secretions, saliva, blood, urine and feces. 
Many of these VOCs likely derive from commensal microbes in the body and are often detect-
able by odor [3]. Pathogenic infection in humans alters both the quantity and composition 
of VOCs produced. As a result of their distinct metabolisms, different pathogens produce 
characteristic VOC profiles, which can often be detected in the headspace of cultures grown 
in vitro [4, 5]. Upon pathogen infection, VOCs released by both the pathogen and infected host 
can potentially be used as a diagnostic signature of the infection state. Analysis of the VOC 
profiles released from clinical samples have yielded VOC biomarkers indicative of specific 
diseases and infections [6–8]. Exhaled breath tests in particular have already proven useful in 
the diagnosis of a broad range of pathologies, including lung disorders, diabetes, gastrointes-
tinal and liver disease, cancer, and pathogen infection [9–11].
VOC signatures uniquely associated with specific pathogens can be clinically relevant for 
diagnosing various infectious diseases, elucidating antibiotic resistance versus susceptibility, 
designing treatment regimens, and monitoring disease progression. The ability to reliably 
distinguish between different pathogenic species, based on their VOC signatures, will facili-
tate the development of rapid, highly-sensitive, and non-invasive diagnostic methods and 
tools, ultimately leading to improved patient outcomes.
2. Overview of clinical sample collection for VOC analysis
There are potential advantages to employing VOC signatures for disease diagnostics, such 
as ease of collection from all patients, including the critically ill, children, and the elderly. 
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Furthermore, longitudinal samples from patients could be more easily obtained to track dis-
ease progression and monitor therapeutic interventions during follow-up studies. The fol-
lowing section describes VOC collection and detection from various types of clinical samples.
2.1. Breath
The vast majority of studies on VOC biomarkers have been conducted using exhaled breath 
samples, as they are the most easily obtained [12]. VOC analysis from breath samples has 
proven useful for diagnosing a wide range of diseases and various infections [11, 13]. Exhaled 
breath contains hundreds of VOCs that can be attributed to either exogenous or endogenous 
sources. Exogenous volatiles include compounds inhaled from the external environment, such 
as the ingestion of food or smoking cigarettes. Endogenous volatiles consist of compounds 
derived from the body. These may include compounds produced by the human body’s 
assortment of commensal bacteria, or in the case of infectious disease, compounds released 
by pathogenic microbes. Endogenous volatiles are transported from different organs via the 
bloodstream to the lungs, excreted via diffusion across the pulmonary alveolar membrane, and 
subsequently exhaled via breath. Distinguishing exogenously derived VOCs from the endog-
enous compounds in a breath sample is a significant challenge in elucidating VOC signatures 
related to disease. The detection of exogenous VOCs in a breath sample may suggest exposure 
to a drug or environmental toxin, which can confound the search for disease biomarkers [14].
VOCs contained in clinical breath samples and bacterial culture headspace samples are pres-
ent at very low levels. To concentrate and analyze breath VOCs, several methods have been 
developed, such as chemical trapping, sorbent trapping, cold trapping, or condensate trap-
ping, followed by thermal desorption to analyze the VOC content [15]. Pre-concentration of 
breath VOCs can further be achieved by solid-phase micro-extraction (SPME), in which dif-
ferent VOCs in a sample are adsorbed by a coated microfiber. These VOCs are then delivered 
directly into the mass spectrometer or other instrument for analysis. A more recently devel-
oped method is membrane extraction with a sorbent interface, which combines sampling and 
pre-concentration in a single step [16]. Exhaled breath condensate (EBC) is another new tech-
nique in which aerosolized micro-droplets from the lower respiratory tract are captured by 
directing the exhaled air through a cooling device, resulting in the accumulation of EBC in 
the collection chamber. In general, EBC collection is an inefficient VOC capture method, due 
to the abundance of non-volatile components in the micro-droplets [11].
2.2. Saliva
Human saliva from healthy subjects is a complex secretion containing peptides, proteins and 
metabolites. Saliva is not a homogenous fluid, but a mixture of different fluids made from 
three distinct salivary glands (the parotid, the submandibular, and the sublingual glands). 
The protein composition of these fluids varies significantly depending on the gland sampled. 
A small amount of saliva is also secreted through hundreds of minor glands located within 
the mouth. As such, when sampling saliva, it is essential to characterize the sample in terms of 
its location. Most studies utilizing saliva samples collect the whole saliva mixture comprised 
of all the various glandular saliva types produced in the mouth [17]. While the protein com-
position arising from each salivary gland is well characterized, the metabolite composition is 
not well understood. However, it has been determined that saliva contains numerous VOCs 
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including alcohols, aldehydes, ketones, carboxylic acids, esters, amines, amides, lactones and 
hydrocarbons [18]. The various bacterial species found in the oral cavity also contribute to 
the chemical composition of saliva through secretion of their metabolic by-products. Analysis 
of sulfur-containing volatile compounds in exhaled breath has linked malodorous breath to 
anaerobic bacterial activity in the oral cavity [19]. Furthermore, exogenous VOCs inhaled 
through the lungs or absorbed through the skin can be excreted into saliva. Other consider-
ations for saliva sampling include time since brushing teeth, time since ingesting sugary or 
acidic foods, evidence of oral injury, and the presence of contaminating fluids such as blood 
[20]. The endogenous VOC profile of human saliva is of particular interest in medical foren-
sics, where oral fluids are routinely analyzed for the presence of drugs or toxins.
2.3. Skin
VOCs emitted from the skin surface are mainly derived from a combination of sweat secreted by 
the sweat glands and sebum, an oily substance secreted by the sebaceous glands. Although some 
of these VOCs result from internal hormonal or metabolic changes, many VOCs appear to be 
derived from commensal skin bacteria that metabolize compounds secreted in sweat and sebum. 
Samples are easily obtained by wiping the patient’s skin with an organic solvent (e.g. acetone), or 
by collecting the VOCs directly from the affected skin onto an absorbent SPME fiber. However, 
care must be taken to avoid contaminating the sample with cosmetics, perfumes, or compounds 
present in the ambient air. This may be especially difficult given that even trace VOCs associated 
with the preservatives found in skin creams and gels are detectable in skin swab samples [21].
2.4. Blood
Blood directly reflects the internal environment of the body, including nutritional, metabolic, 
and immune status. Given that most endogenous VOCs are secreted from cells directly into the 
bloodstream, as the main conduit of communication between different parts of the body, the 
analysis of plasma-derived VOCs has garnered much interest from researchers and clinicians 
alike. Recent work has focused on building up a compendium of blood-borne VOCs in healthy 
human subjects to compare these profiles with patient samples, and thereby identify VOC bio-
markers unique to disease states [22]. However, acquiring blood samples is more invasive than 
either breath or skin, and the requisite pre-treatment of blood to remove red and white blood cells 
has the disadvantage of being very time-consuming. The SPME method has been shown to detect 
a range of volatiles at very low concentrations in human blood, including hydrocarbons (pentane 
and isoprene), ketones (acetone), halogenated compounds (isoflurane), and thioethers (dimethyl 
sulfide). Since blood-borne VOCs can also be liberated in exhaled breath, a greater understand-
ing of blood VOCs will also contribute to the diagnostic potential of breath analysis [23].
2.5. Urine
Given that urine samples are routinely used for diagnosis of disease, urine components and 
urine profiles have been well characterized [24]. The compounds predominantly found in urine 
are intermediate products or end-products of many metabolic pathways. These substances 
contain a variety of chemical motifs, such as ketone, alcohol, furan, pyrrole and sulfide, which 
Biosensing Technologies for the Detection of Pathogens - A Prospective Way for Rapid Analysis24
often generate specific odors. Since there are many components present in urine samples, VOC 
patterns will only be evident after statistical analysis of many patient samples. In addition, con-
siderable variation among individuals has been found in profiles of urine-derived VOCs [7]. 
Importantly, urine components are affected not only by the metabolic status of the body, but 
also significantly by ingested foods and drinks. Therefore, caution must be taken when deter-
mining whether or not any particular VOC biomarker is the result of disease-related changes 
in metabolism or an exogenous cause.
2.6. Feces
Fecal samples contain dietary end-products resulting from intestinal bacterial metabolism and 
digestive and excretory processes. The composition of a patient’s gut microbiota is reflected 
in their fecal sample [25]. As such, fecal VOCs may provide the best non-invasive means of 
diagnosing gastrointestinal and liver diseases. Although many volatile compounds might be 
easily detected in fecal samples, they are still influenced by a range of confounding factors, 
such as diet, gender, age, smoking and certain medications. Also, a large number of VOCs in 
healthy patients is derived from the breakdown of food by intestinal normal flora, and is not 
indicative of any disease. Nevertheless, distinct patterns of VOCs have been discovered in the 
fecal samples of patients with certain bacterial infections, including V. cholerae, C. jejuni and 
C. difficile infections [8, 26].
3. Overview of VOC detection methods and analytical instruments
Over the last two decades, significant advances in analytical chemical techniques and instru-
ments have facilitated the identification of VOCs with improved sensitivity and accuracy. 
Here we summarize the various methods used for VOC detection. The advantages and limi-
tations associated with these techniques and instruments are summarized in Table 1, and 
reviewed in detail elsewhere (see [17, 21, 27, 28]).
Gas chromatography–mass spectrometry (GC–MS) is currently considered the gold standard 
for separation, detection, identification and quantification of VOCs. Samples for GC–MS must 
be in the gaseous phase such that a pure inert carrier gas can transport the sample through the 
chromatographic column. Depending on the VOC concentration, sample pre-concentration 
may be required [21]. Compound resolution improves as the length of the chromatographic 
column increases. Each unique compound is eluted from the column at a different time 
(termed the retention time) and detected by the mass spectrometer via compound ionization 
and measurement of the mass to charge ratio of each ion, thereby generating a unique mass 
spectrum for each compound. The class of volatile that can be detected by GC depends on the 
type of detector used. Examples include time of flight (TOF), plasma ionization, photoioniza-
tion and electron capture detectors [17].
There are also several analytical methods that can be coupled with GC to achieve different 
outputs. As mentioned earlier, SPME followed by GC–MS can provide a solvent-free and eas-
ily automated system for quantifying trace amounts of VOCs [29]. However, it is important 
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to note that SPMEs are coated with different materials for selective compound adsorption. 
Therefore, individual SPMEs may not trap all VOCs present in a sample. GC ion mobility 
spectrometry (GC-IMS), based on separation of ions relative to their gas phase mobility, is 
highly sensitive and enables rapid quantification of separated VOCs, but is not suitable for 
Technique Description Advantages Limitations
GC–MS GC–MS combines separation, GC 
and MS. Separation is typically 
performed by a capillary column, 
with compounds being separated 
by their boiling point and polarity. 
As compounds are eluted, they are 
detected by the mass spectrometer 
as a function of their mass to charge 
ratio. Different MS detectors are 
available, with Time Of Flight (TOF) 
and tandem quadrupoles (MS–MS) 
being the most common.
• Good sensitivity (ppm-ppb)
• Separates, identifies and 
quantifies VOCs all in one
• High chromatographic 
resolution achievable
• Highly reproducible results
• Can analyze VOCs from 
complex mixtures
• Can tentatively identify 
unknown compounds 
based on comparison to 
known mass spectra
• Often requires sample 
pre-concentration
• Lengthy processing and 
analysis times
• Unsuitable for screening 
unknown compounds
• Requires a supply of pure 
inert carrier gas
GC-IMS GC-IMS combines separation, GC and 
IMS. Separation may be performed 
using standard GC capillary columns 
or multi-capillary columns. Dual 
separation occurs first through the 
column and then in the detector 
according to the compound’s gas-
phase ion mobility. Ionized molecules 
are accelerated by an electric field 
towards a Faraday plate, where the 
impact of single ions is detected.
• High sensitivity (ppb-ppt)
• Rapid results
• Best for identifying differ-
ences between non-identi-
cal samples
• Simple to use on site
• Can use ambient air as the 
carrier gas
• Detection is compound-
specific and depends on 
the ion’s mass and charge
• Limited dynamic range 
for quantitation
• Unsuitable for screening 
unknown compounds
• Confusing mass spectra 
can arise when high lev-
els of solvents are present
Direct 
detection
These methods include SIFT-MS, 
IMR-MS, PTR-MS. They are popular 
for their sensitivity, rapid analysis 
times, and ability to extract target 
compounds from samples with little 
or no pre-separation.
• High sensitivity (sub-ppb)
• Rapid results
• Absolute quantification
• Can detect trace com-
pounds in mixtures
• Very expensive
• Unsuitable for screening 
unknown compounds
• PTR-MS only suitable for 
compounds with higher 
proton affinity than water
E-nose A variety of E-nose detectors exist 
today. They generally consist of a 
micro-array of sensors which differ 
from each other in polarity. The 
sample passes through the array, and 
compounds adsorb to varying degrees 
on the different sensors depending 
on their composition. Compound 
adsorption on sensors changes the 
mass or resistance of each sensor, and 
this change is detected to provide 
different outputs.




• Does not require 
sample separation or 
pre-concentration.
• Relatively small, portable, 
and simple to use on site
• Cannot quantify VOCs
• Can only identify known 
patterns of VOCs stored 
in its database
• Unsuitable for screening 
unknown compounds
• Sensitive to high ambi-
ent temperature and 
humidity
Table 1. Summary of most common VOC analytical techniques and their advantages and limitations.
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identifying unknown compounds. The advantage of GC-IMS over GC–MS stems from its 
ability to use ambient air as the carrier gas, which negates the need for a pure inert gas supply 
and allows GC-IMS devices to be portable and particularly useful for breath sample analysis 
[30]. GC flame ionization detection (GC-FID), which is also widely used for breath analysis, 
detects VOCs with high sensitivity and low background noise.
Optical spectroscopic methods, such as laser absorption spectrometry, are also useful for the 
detection and quantification of specific VOCs in a mixture. These methods are highly selec-
tive and sensitive, and can be connected to different types of spectroscopic sensors, such as 
conductive polymer sensors and acoustic wave sensors, to detect the specific VOCs of inter-
est [31]. Non-optical direct-injection methods for VOC measurement include Ion Molecule 
Reaction mass spectrometry (IMR-MS), Selected Ion Flow Tube mass spectrometry (SIFT-MS) 
and Proton Transfer Reaction mass spectrometry (PTR-MS). These methods do not require 
pre-concentration and little or no pre-separation. However, unknown compound identifi-
cation is not possible. SIFT-MS provides real-time absolute quantification of several VOCs 
simultaneously, and therefore is well suited for analyzing clinical samples. A small SIFT-MS-
based analytical instrument has been developed for routine use in a clinical setting [32]. Both 
GC and PTR ionization technology can be coupled to a Time Of Flight mass spectrometer 
(GC-TOF-MS, PTR-TOF-MS), thereby making real-time VOC analysis possible [33, 34].
Finally, devices that electronically mimic the human olfactory system, termed electronic noses 
or ‘e-noses’, have been developed and improved upon since the 1980s [28]. E-noses employ 
several gas sensors combined with pattern recognition software to detect overall odor finger-
prints rather than specific compounds. This may be considered a limitation of the technology, 
as it cannot identify individual biomarkers. On the other hand, unlike GC–MS, e-noses have the 
advantage of being able to differentiate between non-identical samples without the need to sep-
arate the mixture into its individual components, a process which can be highly variable based 
on the technique(s) used. E-noses provide rapid results, but are limited by the VOC patterns 
they are programmed to detect, and thus cannot be used for screening unknown compounds. 
Before e-noses can be used routinely for practical diagnosis, it will be necessary to improve 
their accuracy and sensitivity to enable reliable recognition of a large number of VOC profiles.
While the informatics approaches used in conjunction with the aforementioned instruments can 
vary, three main methods are typically used, alone or concurrently, to confirm VOC identifica-
tion: (1) comparing mass spectra data obtained to those in reference libraries and databases, (2) 
comparing mass spectra and peak retention times to those obtained from pure standard com-
pounds, and (3) comparing mass spectra data obtained to those characterized in the literature.
4. VOC analysis for detecting infectious diseases
A growing number of studies clearly demonstrate the efficacy of VOC analysis in identify-
ing a wide range of non-infectious diseases, including inflammatory disease [35], diabetes 
[36], lung cancer [37], and even Alzheimer’s disease [38]. In the context of infectious diseases, 
VOC detection has clinical value in three aspects of diagnostics: (1) identifying the absence 
of pathogens (i.e. no antibiotic treatment), (2) identifying the presence of a specific pathogen 
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(i.e. start appropriate antibiotic treatment), and (3) distinguishing between pathogenic spe-
cies (i.e. determine antibiotic resistance versus sensitivity for the pathogen to guide treatment 
regimens). Examples of candidate VOCs identified as being associated with specific patho-
gens are summarized in Table 2. It should be noted here that many researchers emphasize 
the importance of considering the entire VOC profile of a pathogen and how it differs from 
another pathogen, rather than relying on any single VOC biomarker to reveal an association.
4.1. Respiratory infections
Although pathogens are capable of producing a large variety of VOCs, very few metabolites 
are produced exclusively by only one bacterial species. Particularly in cases of polymicrobial 
pulmonary infections, such as cystic fibrosis (CF), identification of the specific bacterial species 
responsible for the pathology is critical for correct diagnosis and treatment. Since patient progno-
ses can decline rapidly following these types of opportunistic infections, particularly in children, 
early detection is vital for the timely initiation of appropriate therapies [48]. GC-TOF-MS analysis 
of breath samples from CF patients has demonstrated that a distinctive VOC profile consist-
ing of 22 compounds can discriminate CF patients from healthy controls with 100% accuracy. 
Furthermore, within the CF patients analyzed, a profile of 14 VOCs was able to correctly discrim-
inate between patients with Pseudomonas aeruginosa positive cultures compared to those with 
negative cultures [49]. Interestingly, genotypically diverse strains of P. aeruginosa under the same 
culture conditions have been shown to exhibit a high degree of variability in detectable VOCs 
[50], indicating that additional CF patients need to be studied to determine which VOCs are truly 
discriminatory. In another study, distinct VOCs were characterized in the culture headspaces 
of four different opportunistic pathogens (P. aeruginosa, Staphylococcus aureus, Stenotrophomonas 
maltophilia and the Burkholderia cepacia complex) that cause lung and airway infection in CF 
patients, providing additional VOC signatures to test in infected host systems [51].
Pathogen Infectious disease(s) VOC candidates for disease biomarkers Reference(s)
M. tuberculosis Active pulmonary 
tuberculosis
1-methyl-naphthalene, methyl nicotinate, 
1,4-dimethyl-cyclohexane
[13, 39, 40]
C. jejuni Ulcerative colitis, 
diarrhea
Butanoic acid, 1-octen-3-ol, 1-butoxy-2-propanol [8]
C. difficile Ulcerative colitis, 
diarrhea
Ethanol, Butanol, Isopropanol [8]
V. cholera Cholera Dimethyl disulfide, p-menth-1-en-8-ol [9, 26]
H. pylori Peptic ulcers Hydrogen cyanide [41]
S. aureus Sinusitis, pneumonia acetoin, hydroxyacetone, acetic acid, isovaleric acid, 
acetaldehyde, 2-propanol, 3-methyl-1-butanol
[42, 43]
P. aeruginosa Sinusitis, pneumonia 2-aminoacetophenone, pyrrole, 1-vinylaziridine, 
3-methylpyrrole, 1-undecene, 2-nonanone, methyl 
thiocyanate
[43–46]
K. pneumoniae Bronchitis, pneumonia butyraldehyde, octyl acetate, tridecanol, dodecenal, 
butanoic acid
[47]
Table 2. Examples of VOCs associated with specific pathogens and infectious diseases.
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Mycobacterium tuberculosis infection is another respiratory disease that has been the focus 
of much VOC research. GC–MS analysis of urine sample headspaces was used to identify 
and distinguish VOC profiles from tuberculosis (TB) patients and healthy controls. Five bio-
marker compounds were able to discriminate between these two groups with 98.8% accuracy: 
alpha-xylene, isopropyl acetate, 3-pentanol, dimethylstyrene, and cymol. These compounds 
also served to discriminate TB patients from patients with lung cancer and COPD [52]. In 
another study using GC–MS analysis of exhaled breath, active pulmonary TB could be dis-
tinguished from non-active TB with 85% accuracy. 1,3,5-Trimethylbenzene was identified 
in active pulmonary TB, whereas 1,2,3,4-tetramethylbenzene was a biomarker for the non-
active state. Exhaled breath samples from all the TB patients contained the M. tuberculosis-
associated biomarkers 1-methyl-naphthalene and 1,4-dimethyl-cyclohexane, which were also 
observed in in vitro cultures [39]. Other studies focusing on headspace VOCs from in vitro 
cultured Mycobacterium species have revealed several metabolites of nicotinic acid, four of 
which are considered specific for M. tuberculosis and M. bovis strains: methyl phenylacetate, 
methyl p-anisate, methyl nicotinate, and o-phenylanisole [53]. Methyl nicotinate has also been 
detected at high levels in the exhaled breath of smear-positive TB patients [40]. VOCs derived 
from in vitro M. tuberculosis cultures are distinct from those VOCs produced by an infected 
host, as a result of oxidative stress. Volatiles related to oxidative stress include alkanes and 
methylated alkane derivatives, whereas in vitro-defined VOCs of M. tuberculosis origin include 
cyclohexane, benzene, decane, and heptane derivatives [13].
4.2. Gastrointestinal infections
Fecal samples taken from patients suffering from various forms of infectious diarrhea have 
revealed characteristic VOC profiles depending on the causative pathogen. For example, the 
absence of hydrocarbons and terpenes indicated a Campylobacter infection, whereas the absence 
of furans and indoles indicated a Clostridium difficile infection [54]. Another study focusing on 
ulcerative colitis, a disease marked by inflammation of the colonic mucosa, found that while 
hundreds of volatiles were detectable in donor fecal samples, distinct VOC patterns could 
discriminate between healthy controls and patients infected with C. jejuni and C. difficile [8]. 
Typhoid fever is caused by Salmonella typhi infection and is spread by consuming contaminated 
water or food. VOC metabolite profiles specific to S. typhi can be detected by GC–MS from the 
blood samples of typhoid patients. Importantly, such metabolite profiles can also differentiate 
between Salmonella typhi and Salmonella paratyphi A infections, enabling targeted therapies [55].
4.3. Urinary tract infections
In cases of urinary tract infection (UTI), appropriate and effective therapy is heavily dependent on 
early diagnosis. UTIs are most frequently caused by Escherichia coli and other enteric pathogens 
such as Enterococci, Klebsiella, Staphylococci, and Proteus species, and also fungal pathogens such 
as Candida albicans [56]. Volatile metabolites released by these pathogens are detectable in the 
headspace of urine samples [56–58]. E-noses have proven particularly useful in recognizing the 
VOC patterns of healthy versus infected urine samples, though sample pre-concentration is often 
required. The relative efficacies of the various types of e-noses currently in use were compared in a 
recent review [57]. Since urine contains a complex mixture of VOCs that is relatively  well-defined 
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[24], significant changes to the VOC profile of patients with UTIs may serve as diagnostic bio-
markers of infection. To this end, more sensitive methodologies that do not require sample pre-
incubation are needed to enable the efficient routine diagnosis of UTIs using VOC profiling.
4.4. Blood infections
A review of multiple studies revealed that distinct VOC signatures are produced by each of 
the six most abundant and pathogenic bacteria in sepsis (Staphylococcus aureus, Streptococcus 
pneumoniae, Enterococcus faecalis, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia 
coli). While all six species produced isopentanol, formaldehyde, methyl mercaptan, and trimeth-
ylamine, each species also produced unique key compounds that can be used as specific VOC 
signatures [59]. Another blood-borne disease, malaria, is transmitted by mosquitoes that intro-
duce the Plasmodium falciparum parasite into the blood of the host. Breath-based VOC analysis 
offers a rapid and non-invasive alternative to the current approach of visualizing P. falciparum 
on stained blood films. A recent study identified nine malaria-associated VOCs: carbon dioxide, 
isoprene, acetone, benzene, cyclohexanone, and four types of thioethers. The concentrations of 
these compounds varied significantly as the disease progressed. Following antimalarial drug 
treatment, parasite clearance correlated strongly with a decline in VOC levels [60]. Notably, 
another recent study found that blood cultures of E. coli and S. aureus yielded different VOC 
profiles before and after exposure to gentamicin or flucloxacillin, demonstrating that antibiotic 
susceptibility status can also be rapidly evaluated by VOC analysis [61].
5. Challenges in the clinical application of VOC analysis
There remain both logistical and technical challenges to the translation of VOC analysis from 
the research laboratory to the clinical setting. On the logistical side, the analytical instruments 
required for VOC detection are very expensive and require a large footprint and specialized 
training to operate and analyze the data. Furthermore, the methods are time-consuming and 
not readily scalable for high-throughput sample processing. There remains a lack of stan-
dardization for procedures in sample collection, pre-concentration, and storage, which are 
essential for effective clinical implementation.
From a technical standpoint, it is important to emphasize that the presence of a unique pattern 
of VOCs (constituting a complete VOC signature), rather than a single VOC biomarker, will 
be necessary for bacterial species identification [34]. Diagnostic tests based on a single VOC 
biomarker do not appear possible, given the fact that all pathogens produce a wide range of 
overlapping volatile metabolites. It should also be noted that the conspicuous absence of certain 
volatile compounds from a culture or sample actually forms part of the distinct VOC signature 
for a particular pathogen [36]. Furthermore, the specific profile of VOCs detectable in vitro is 
largely dependent on the bacterial growth state and density (e.g. logarithmic versus stationary 
phase), sample storage conditions (e.g. short-term versus long-term), and the type of culture 
media used [34, 62, 63]. To confound analysis further, patient samples are far less well-defined 
than laboratory cultures of reference strains, and therefore vary greatly in terms of growth phase, 
host response, viscosity, confounding co-morbidities, and medications (including antibiotics) 
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[43, 61, 64]. Therefore, reproducibility of VOC signatures, even in patients infected with the 
same pathogen, remains a challenge given the variability between individual patient samples.
If VOCs from primary patient samples are to be used effectively for clinical diagnostic pur-
poses, we must recognize the confounding factors associated with VOC analysis. Firstly, the 
environment of the human body is entirely different from in vitro growth media for pathogen 
and human cell culture, thereby resulting in a completely different set of metabolic by-prod-
ucts [43]. Secondly, genotypic variability between different strains of a pathogen can strongly 
influence the types and concentrations of volatile metabolites detected [50]. Thirdly, the 
human body mounts an inflammatory response against pathogen infection, potentially lead-
ing to a change in bacterial and host metabolism. Future studies should address the metabolic 
differences between infectious and non-infectious inflammatory responses [65]. Fourthly, 
VOCs derived from exogenous sources, such as the host environment and diet, can easily 
contaminate a sample [66]. Before diagnostic tests based on endogenously produced VOCs 
can be routinely used on patient samples, it is necessary to definitively separate true biomark-
ers from contaminating components. Lastly, the human body plays host to an entire micro-
biome unique to each individual. It may be that these commensal bacteria produce many 
metabolites that are indistinguishable from those generated by disease-causing pathogens, 
and therefore may interfere with a VOC-based diagnostic test [67].
6. Conclusions and future perspectives
In the last two decades, diverse studies have used emerging and established technologies 
to assess the applicability of the VOC profiling approach to the diagnosis and treatment of 
pathogenic infections. At present, numerous studies have identified VOC profiles and can-
didate biomarkers for certain infectious diseases, which allow researchers to discriminate 
between different pathogenic species and between healthy and diseased individuals. VOC 
analysis continues to be a rapidly expanding field of inquiry. However, as outlined in the pre-
vious section, VOC-based diagnostics will require further development and vetting of repro-
ducibility before transition from the laboratory to the clinic.
Existing VOC profiles and candidate biomarkers must still be corroborated across several coor-
dinated studies before there can be sufficient confidence in their diagnostic efficacy. For example, 
independent in vitro studies that investigate the same organism, but subjected to different sam-
pling methods and analytical techniques, have led to identification of different VOC patterns. 
Similarly, direct comparisons of independent clinical studies are difficult, given that experimen-
tal design and parameters differ between studies. In addition, very few studies to date have 
compared individuals with active disease to individuals at other disease stages (e.g. comparison 
of active TB and latent TB). Likewise, little data exists on the effect that comorbidities or co-
infections (e.g. TB co-infection with HIV) may have on the range and type of detectable VOCs. 
Targeted studies are still required to fully characterize VOC disease signatures and to further 
evaluate the diagnostic accuracy of these biomarkers in patient samples. It is clear that before 
this approach can become integrated into routine clinical practice, it must first be validated by 
clinical trials using sufficiently large numbers of test subjects across a range of infections.
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Despite the challenges, it is foreseeable that continued research in this area may pave the way 
for the design of unique diagnostic tools, such as disease-specific sensor arrays and targeted 
metabolite breathalyzers, that could also have potential applications in forensics, pharmaco-
kinetics, and toxicology. Furthermore, the development of portable, sensor-based devices for 
the personalized monitoring of disease states and therapy progress would represent a clear 
advancement beyond the current state-of-the-art in clinical practice. In the long term, such 
tools could enable a more selective approach to antimicrobial drug use, while also opening up 
the possibility of individually tailored treatments.
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